What is Singulex?
Founded in 1997 and headquartered in Alameda, California, Singulex operates at the intersection of advanced scientific discovery and clinical diagnostics. The company is recognized as a pioneer in single-molecule counting technology, a platform that provides unprecedented sensitivity in detecting biomarkers. By enabling the identification of low-abundance proteins and molecules, Singulex empowers clinicians and researchers to detect diseases at their earliest, most treatable stages. This technological edge has allowed the firm to transition from a research-focused entity into a critical player in the enterprise-level diagnostic landscape, effectively bridging the gap between laboratory innovation and bedside application.
How much funding has Singulex raised?
Singulex has raised a total of $151.8M across 6 funding rounds:
Series C
$8.4M
Series D
$19M
Series E
$19M
Series F
$15.3M
Debt
$40M
Private Equity
$50M
Series C (2006): $8.4M with participation from BioProfile Holding Company, Prolog Capital, and Fisk Ventures
Series D (2009): $19M led by OrbiMed and Jafco ventures
Series E (2009): $19M supported by Fisk Ventures, JAFCO Japan, and OrbiMed
Series F (2012): $15.3M, investors not publicly disclosed
Debt (2013): $40M backed by Silicon Valley Bank and Oxford Finance
Private Equity (2016): $50M with participation from Grifols
Key Investors in Singulex
Grifols
A global healthcare leader based in Spain, Grifols specializes in plasma-derived medicines and diagnostic solutions, focusing on long-term sustainable growth and innovation in the healthcare value chain.
OrbiMed
A specialized investment firm dedicated to the healthcare sector, OrbiMed manages capital across biopharmaceuticals and diagnostics, providing deep operational expertise to support life sciences innovation.
Silicon Valley Bank
A premier financial institution providing commercial banking and specialized debt solutions to the innovation economy, with a strong focus on supporting high-growth healthcare and life sciences enterprises.
What's next for Singulex?
With the infusion of capital from its most recent strategic financing, Singulex is poised to accelerate its commercialization efforts and deepen its integration into global healthcare systems. The company's strategic roadmap likely involves scaling its diagnostic platform to meet the increasing demand for high-precision testing in chronic disease management. By leveraging its established partnerships with major healthcare stakeholders, Singulex is well-positioned to capitalize on the shift toward personalized medicine, where the ability to quantify minute biological changes is becoming a standard requirement for therapeutic efficacy and patient monitoring.
See full Singulex company page
